These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 26215564)

  • 1. HIV-1 Vpu utilizes both cullin-RING ligase (CRL) dependent and independent mechanisms to downmodulate host proteins.
    Ramirez PW; DePaula-Silva AB; Szaniawski M; Barker E; Bosque A; Planelles V
    Retrovirology; 2015 Jul; 12():65. PubMed ID: 26215564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release.
    Tervo HM; Homann S; Ambiel I; Fritz JV; Fackler OT; Keppler OT
    Retrovirology; 2011 Feb; 8():9. PubMed ID: 21310048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of BST-2 by Type I Interferons Reduces the Capacity of Vpu To Protect HIV-1-Infected Cells from NK Cell Responses.
    Prévost J; Pickering S; Mumby MJ; Medjahed H; Gendron-Lepage G; Delgado GG; Dirk BS; Dikeakos JD; Stürzel CM; Sauter D; Kirchhoff F; Bibollet-Ruche F; Hahn BH; Dubé M; Kaufmann DE; Neil SJD; Finzi A; Richard J
    mBio; 2019 Jun; 10(3):. PubMed ID: 31213558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin.
    Song YE; Cyburt D; Lucas TM; Gregory DA; Lyddon TD; Johnson MC
    Viruses; 2018 Oct; 10(10):. PubMed ID: 30347660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.
    Douglas JL; Viswanathan K; McCarroll MN; Gustin JK; Früh K; Moses AV
    J Virol; 2009 Aug; 83(16):7931-47. PubMed ID: 19515779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 Vpu Downmodulates ICAM-1 Expression, Resulting in Decreased Killing of Infected CD4
    Sugden SM; Pham TNQ; Cohen ÉA
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28148794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking.
    Mitchell RS; Katsura C; Skasko MA; Fitzpatrick K; Lau D; Ruiz A; Stephens EB; Margottin-Goguet F; Benarous R; Guatelli JC
    PLoS Pathog; 2009 May; 5(5):e1000450. PubMed ID: 19478868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. β-TrCP dependency of HIV-1 Vpu-induced downregulation of CD4 and BST-2/tetherin.
    Blanchet FP; Mitchell JP; Piguet V
    Curr HIV Res; 2012 Jun; 10(4):307-14. PubMed ID: 22524179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of β-TrcP-dependent ubiquitination of p53 by HIV-1 Vpu promotes p53-mediated apoptosis in human T cells.
    Verma S; Ali A; Arora S; Banerjea AC
    Blood; 2011 Jun; 117(24):6600-7. PubMed ID: 21521785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The C-Terminal End of HIV-1 Vpu Has a Clade-Specific Determinant That Antagonizes BST-2 and Facilitates Virion Release.
    Sharma S; Jafari M; Bangar A; William K; Guatelli J; Lewinski MK
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30867310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation.
    Mangeat B; Gers-Huber G; Lehmann M; Zufferey M; Luban J; Piguet V
    PLoS Pathog; 2009 Sep; 5(9):e1000574. PubMed ID: 19730691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes.
    Iwabu Y; Fujita H; Kinomoto M; Kaneko K; Ishizaka Y; Tanaka Y; Sata T; Tokunaga K
    J Biol Chem; 2009 Dec; 284(50):35060-72. PubMed ID: 19837671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ubiquitination of BST-2 protein by HIV-1 Vpu protein does not require lysine, serine, or threonine residues within the BST-2 cytoplasmic domain.
    Gustin JK; Douglas JL; Bai Y; Moses AV
    J Biol Chem; 2012 Apr; 287(18):14837-50. PubMed ID: 22383521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The human immunodeficiency virus type 1 accessory protein Vpu induces apoptosis by suppressing the nuclear factor kappaB-dependent expression of antiapoptotic factors.
    Akari H; Bour S; Kao S; Adachi A; Strebel K
    J Exp Med; 2001 Nov; 194(9):1299-311. PubMed ID: 11696595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vpu of a Simian Immunodeficiency Virus Isolated from Greater Spot-Nosed Monkey Antagonizes Human BST-2 via Two AxxxxxxxW Motifs.
    Yao W; Yoshida T; Hashimoto S; Takeuchi H; Strebel K; Yamaoka S
    J Virol; 2020 Jan; 94(2):. PubMed ID: 31666374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activities of transmitted/founder and chronic clade B HIV-1 Vpu and a C-terminal polymorphism specifically affecting virion release.
    Jafari M; Guatelli J; Lewinski MK
    J Virol; 2014 May; 88(9):5062-78. PubMed ID: 24574397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serine-threonine ubiquitination mediates downregulation of BST-2/tetherin and relief of restricted virion release by HIV-1 Vpu.
    Tokarev AA; Munguia J; Guatelli JC
    J Virol; 2011 Jan; 85(1):51-63. PubMed ID: 20980512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 Vpu's lipid raft association is dispensable for counteraction of the particle release restriction imposed by CD317/Tetherin.
    Fritz JV; Tibroni N; Keppler OT; Fackler OT
    Virology; 2012 Mar; 424(1):33-44. PubMed ID: 22222210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vpu-Mediated Counteraction of Tetherin Is a Major Determinant of HIV-1 Interferon Resistance.
    Kmiec D; Iyer SS; Stürzel CM; Sauter D; Hahn BH; Kirchhoff F
    mBio; 2016 Aug; 7(4):. PubMed ID: 27531907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential Vpu-Mediated CD4 and Tetherin Downregulation Functions among Major HIV-1 Group M Subtypes.
    Umviligihozo G; Cobarrubias KD; Chandrarathna S; Jin SW; Reddy N; Byakwaga H; Muzoora C; Bwana MB; Lee GQ; Hunt PW; Martin JN; Brumme CJ; Bangsberg DR; Karita E; Allen S; Hunter E; Ndung'u T; Brumme ZL; Brockman MA
    J Virol; 2020 Jul; 94(14):. PubMed ID: 32376625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.